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The membrane and channel protein connexin-43 (Cx43), as well as the cytokine transform-
ing growth factor (TGF) β, suppress proliferative growth in cardiomyocytes and other cell
types. Previously we showed that the inhibitory effect of Cx43 is canceled when Cx43
becomes phosphorylated at serine (S) 262 in response to mitogen stimulation. We have
now asked if theTGFβ-triggered inhibition of DNA synthesis is associated with changes in
Cx43 phosphorylation at S262. Conversely, we investigated if inhibition ofDNAsynthesis by
overexpressed Cx43 is dependent on engaging TGFβ signal transduction. We report that
TGFβ acutely prevented mitogen-induced Cx43 phosphorylation at S262, while chronic
inhibition of TGFβ signal transduction raised baseline levels of endogenous phospho-
S262-Cx43 without affecting total Cx43. Inhibition of baseline TGFβ signal transduction
through (a) inhibitingTGFβ receptor I (TGFβRI) with SB431542, (b) inhibitingTGFβ receptor II
(TGFβRII) by overexpressing dominant-negative (DN)TGFβRII, (c) inhibiting the downstream
signaling mediator Smad2 by overexpressing DN Smad2, each separately increased
baseline cardiomyocyte DNA synthesis, but could not reverse DNA synthesis inhibition
by overexpressed Cx43. It is suggested that inhibition of cardiomyocyte DNA synthesis
by TGFβ/TGFβRI/II/phospho-Smad2 signaling is mediated, at least in part, by reducing
endogenous phospho-S262-Cx43 levels.
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INTRODUCTION
Cardiomyocytes, the contractile functional units of the heart
pump, are proliferative during the embryonic and early neona-
tal stages. Subsequently cardiac increases in mass and size occur
mainly by increased size of individual myocytes (hypertrophy)
rather than cell proliferation (Ahuja et al., 2007). Ischemic heart
disease and myocardial infarction cause damage and loss of func-
tional myocardium, which is replaced mainly by scar tissue,
resulting in maladaptive remodeling and heart failure. Endoge-
nous capacity for regeneration after extensive injury resulting in
cell death is inadequate to replace lost cardiac tissue; nevertheless,
a small percentage of adult cardiomyocytes maintain the capacity
to enter the cell cycle (Bergmann et al., 2009), and this percentage
increases after myocardial infarction (Senyo et al., 2013), indica-
tive of an attempt for a regenerative response. To improve cardiac
regeneration after injury it is important to identify factors and
mechanisms stimulating or inhibiting cardiomyocyte prolifera-
tion. This understanding can provide strategies for stimulating
or dis-inhibiting cardiomyocyte proliferation as may be needed
during cardiac repair after myocardial infarction.
Overexpression as well as knock-down studies have shown
that the membrane and gap junction channel phosphoprotein
connexin-43 (Cx43) inhibits DNA synthesis in cardiomyocytes
and several other cell types (Doble et al., 2004; Kardami et al.,
2007; Zhang et al., 2008; Matsuyama and Kawahara, 2009). The
mechanism by which Cx43 affects cell proliferation includes sig-
niﬁcant effects on gene expression; and does not require the
channel-forming ability of the molecule (Kardami et al., 2007). It
is important to note that the ability of Cx43 to inhibit cell prolif-
eration is regulatable: mitogen-induced phosphorylation of Cx43,
or the C-terminal of Cx43 (Cx43-CT) at S262, was shown to can-
cel their inhibitory effect on DNA synthesis (Doble et al., 2004;
Dang et al., 2006). Mitogens such as ﬁbroblast growth factor 2
(FGF-2) stimulate cardiomyocyte proliferation, as well as Cx43
phosphorylation at S262.
The proliferative action of FGF-2 is counteracted by another
multifunctional protein, transforming growth factor (TGF)
β, which inhibits cardiomyocyte proliferation (Kardami, 1990;
Sheikh et al., 2004). Proliferative growth suppression by Cx43
may be linked to TGFβ signaling: Cx43 was reported to poten-
tiate TGFβ signaling in the atria-derived cardiomyocyte cell line
HL-1, by competing with the downstream mediator of TGFβ
signal transduction, Smad2, for binding to tubulin (Dai et al.,
2007). This competitive binding released Smad2 from micro-
tubules, thus making it available for phosphorylation by TGFβ
receptor I (TGFβRI), followed by nuclear translocation, and acti-
vation of TGFβ responsive genes (Dai et al., 2007). In addition,
TGFβ is known to upregulate Cx43 expression in a number of
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cell types including epithelial cells and vascular smooth muscle
cells, and this upregulation may contribute to inhibition of DNA
synthesis (Rama et al., 2006; Tacheau et al., 2008).
In the present study, we addressed the potential relationship
between Cx43 and TGFβ-mediated inhibition of cardiomyocyte
DNA synthesis. Our data showed that TGFβ signaling inhib-
ited the growth factor-induced phosphorylation of endogenous
Cx43 at S262. On the other hand, inhibition of cardiomyocyte
DNA synthesis by overexpressedCx43 did not require downstream
activation of TGFβ-related signals such as TGFβRI, TGFβRII, or
Smad2. Overall our data suggest that Cx43-mediated inhibition
is downstream of early TGFβ signal transduction, and that the
mechanism of TGFβ-triggered inhibition of cardiomyocyte DNA
synthesis includes downregulation of endogenous pS262-Cx43.
MATERIALS AND METHODS
ANIMALS
One-day-old Sprague Dawley rat pups were obtained from the
Central Animal Care Facility at the University of Manitoba. This
study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals by
the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). Approval for use of rat pups was obtained by the
Protocol Management and Review Committee of the University
of Manitoba.
REAGENTS
Rabbit polyclonal antibodies recognizing: (i) total Cx43 (phos-
phorylated as well as unphosphorylated), were raised in-house
against a synthetic peptide containing Cx43 residues 367–382;
the immune serum was used at 1:10,000 dilution for western
blotting, (ii) anti-phospho-(p) 262-Cx43 antibodies were pur-
chased from Santa Cruz Biotechnology (CA,USA), as a 200-μg/ml
solution, and were used at 1:1000 dilution. These antibodies
have been characterized and described previously (Doble et al.,
2004; Srisakuldee et al., 2009). Anti-bromodeoxyuridine (BrdU)
antibodies (GE Biosciences) were used at 1:1000 dilution. Anti-
phospho-(p)Smad2(Ser465/467), or anti-Smad2 antibodies were
purchased fromUpstate or Cell Signaling Technology (MA,USA),
respectively and used at 1:1000 dilution. Mouse monoclonal anti-
α-actinin (1:200) and rabbit anti-actin (1:1000) antibody were
from Sigma (USA). Goat anti-mouse and anti-rabbit HRP (horse
radish peroxidase) secondary antibodies, were obtained from Bio-
Rad (CA, USA) and used as per manufacturer’s instructions. The
TGFβRI inhibitor SB431542was purchased fromTocris Bioscience
(Bristol, UK). TGFβ1 was purchased from R&D Systems (USA),
and used at 5 ng/ml. Recombinant 18 kDa FGF-2 was produced
in-house as we have described (Jiang et al., 2002, 2004), and used at
10 ng/ml. Adenoviral vectors expressing wild type-Cx43, mutant
S262A-Cx43 or truncated Cx43-CT (residues 247–382), have been
described previously (Doble et al., 2004; Kardami et al., 2007), and
were used at low titers (2 m.o.i; multiplicity of infection), achiev-
ing modest overexpression, namely a two- to threefold increase
in total Cx43 (Srisakuldee et al., 2009). The adenoviral vector
expressing TGFβRII-dominant-negative (DN) has been described
(Sheikh et al., 2004) and was used at 50 m.o.i. Adenoviral vectors
expressing DN Smad2-DN, or Smad3-DN have been described in
(Uemura et al., 2005) and were generous gifts from Dr. Rebecca
Wells (University of Pennsylvania School of Medicine, PA, USA);
they were used at 100 m.o.i.
WESTERN BLOT ANALYSIS
Lysates were analyzed on 10% polyacrylamide gels, at 10 μg
protein/lane, as described previously (Srisakuldee et al., 2009).
Broad range (6.5–200 kDa) molecular mass standards (Bio-Rad)
were used in all analyses. Protein concentration was deter-
mined by the bicinchoninic acid (BCA) protein assay reagent
(Pierce) followed by spectrophotometry. The proteins on the gel
were electrophoretically transferred to polyvinylidene diﬂuoride
membranes. Antigen–antibody complexes were visualized using
enhanced chemiluminescence (ECLplus), from Amersham Phar-
macia. Densities of western blot bands were determined using the
Bio-RadModel GS-800 densitometer withMolecular Analyst soft-
ware (Bio-Rad). Band densities were adjusted based on the density
of corresponding loading controls.
NEONATAL RAT VENTRICULAR MYOCYTE CULTURES
Cardiomyocytes were isolated from the ventricles of 1-day-old
rat pups according to standard procedures (Doble et al., 1996).
For studies on DNA synthesis, myocytes were plated on collagen-
coated coverslips at 400,000 cells/35 mm well, in the presence
of 10% bovine calf serum supplemented with FGF-2 (10 ng/ml)
and routinely maintained in this type of medium in experi-
ments using adenoviral vector gene transfer. In some experiments,
myocytes were placed in a low serum medium (0.5% bovine calf
serum supplemented with 0.5% bovine serum albumin (BSA),
1% penicillin/streptomycin, 0.04% vitamin C, 0.1% insulin, 0.1%
transferrin/selenium) for 48 h, followed by stimulation with FGF-
2 (10 ng/ml, 30 min) in the presence or absence of 15 min
pre-treatment with TGFβ (5 ng/ml).
BROMODEOXYURIDINE LABELING INDEX
As described previously (Doble et al., 2004). Brieﬂy, cardiomy-
ocytes cultured on coverslips were incubated with BrdU (3μg/ml)
for 8–12 h prior to the termination of various experiments. Cover-
slips were then ﬁxed with 1% paraformaldehyde for 15 min in the
cold, and then treated with 0.07 M NaOH for 2 min at room tem-
perature. Labeling for sarcomeric α-actinin (exclusively cytosolic
aswell as cardiomyocyte-speciﬁc), forBrdU(to identify nuclei syn-
thesizing DNA), and Cx43 (to ascertain Cx43 overexpression after
transfection) was achieved using mouse monoclonal antibodies
against α-actinin, against BrdU, and rabbit polyclonal antibodies
against Cx43. Coverslips were also counterstained for DNA, with
Hoechst 33342. A minimum of 24 randomly selected visual ﬁelds,
distributed in three coverslips, were observed under epiﬂuores-
cence optics, photographed, and individually scored for numbers
of BrdU-positive cardiomyocyte nuclei, over total cardiomyocyte
nuclei (BrdU labeling index).
STATISTICS
The GraphpadStat and SigmaStat software programs were used
for data analysis. Data are presented as mean ± SEM (standard
error of the mean). Statistical analysis was performed using either
one-way ANOVA to compare more than two groups or two-way
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ANOVA to compare more than two groups with two independent
variables. P< 0.05was considered statistically signiﬁcant. P< 0.01
was considered statistically very signiﬁcant.
RESULTS
EFFECT OF TGFβ ON RELATIVE CARDIOMYOCYTE pS262-Cx43 LEVELS
Our previous studies have demonstrated that cardiomyocytes
maintained in culture under growth-stimulating conditions, are
nevertheless subjected to a degree of mitotic suppression by“base-
line TGFβ,” representing TGFβ present in serum, and/or made by
myocytes and the small amount of contaminating ﬁbroblasts, in
culture. Inhibiting this baseline TGFβ signaling potentiated the
ability of growth factors such as FGF-2 to stimulate cardiomy-
ocyte proliferation (Doble et al., 2004; Sheikh et al., 2004). As we
have found a positive relationship between growth factor-induced
Cx43 phosphorylation at S262, and the ability of growth factors to
stimulate cardiomyocyte proliferation, we asked whether inhibi-
tion of baseline TGFβ signal transduction would inﬂuence levels
of endogenous pS262-Cx43, in culture.
Primary cultures of neonatal cardiac myocytes, placed under
conditions stimulating proliferative growth (10% bovine calf
serum, plus 10 ng/ml FGF-2) were exposed to a pharmacological
inhibitor of TGFβRI (SB431542), or subjected to overexpression
of DN versions of either TGFβRII or Smad2, through adenovirally
mediated transient gene transfer. One day following these manip-
ulations cell lysates were analyzed for total as well as pS262-Cx43
by western blotting. Two types of control cultures were used: in
the ﬁrst, cells were kept in growthmediumwithout any treatment,
while in the second cells were treated with an empty adenoviral
vector. As shown in Figure 1, both types of controls elicited signals
of similar intensity for pS262-Cx43, as well as total Cx43, indicat-
ing that the adenoviral vector had no effect on Cx43. Treatment
FIGURE 1 | Inhibition ofTGFβ signaling increases baseline cardiomyocyte
Cx43 phosphorylation at S262. (A)Western blots of cardiomyocyte lysates
probed for total Cx43 (Cx43), pS262-Cx43, and β-tubulin (loading control), as
indicated. Samples shown represent ﬁve groups, including two types of
controls (C), such as myocytes subjected to no treatment (Control), or
exposed to an empty adenoviral vector (Vector); the two controls produced
similar data. The remaining three groups were treated with TGFβ signaling
inhibitors (I), such as SB431542 (20 μM) and adenoviral vectors expressing
TGFβRII-DN or Smad2-DN, as indicated. All three groups showed increased
signal for pS262-Cx43, compared to control groups. (B) Combined
densitometry data (optical density, OD units) comparing relative pS262-Cx43,
total Cx43, or the ratio of pS262-Cx43/total Cx43 between control, C (n = 4),
and I-treated groups (n = 6). **, *, and ns denote P < 0.01, P < 0.05, and
P < 0.05.
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of cardiomyocytes with inhibitors of TGFβ signal transduction
elicited a signiﬁcant increase in pS262-Cx43 (Figure 1), but had
no signiﬁcant effect on total Cx43.
Probing with antibodies recognizing total Cx43 showed that
the majority of Cx43 migrated at 45 kDa, representing extensively
phosphorylated Cx43, with a faint signal near 41 kDa, repre-
senting unphosphorylated or minimally phosphorylated Cx43.
This pattern is typical for cardiomyocytes (Doble et al., 2004;
Srisakuldee et al., 2009). Probing with anti-pS262-Cx43 detected
bands migrating near 41 as well as 45 kDa, indicating that, under
“growth stimulation” conditions, phosphorylation at the S262 site
can occur, respectively, on Cx43 that lacks substantial phosphory-
lation at other sites, as well as on Cx43 extensively phosphorylated
at other sites. Please note that any shift in motility that might be
caused by phosphorylation at a single site (S262) would not be
detectable by standard one-dimensional electrophoresis as used
here. Inhibition of TGFβ signal transduction upregulated both
the faster and slower migrating pS262-Cx43 bands. Figure 1B is
showing densitometric results representing the sum of Cx43 or
pS262-Cx43 bands.
In another experiment, we tested the effect of TGFβ on the
acute FGF-2-induced stimulation of Cx43 phosphorylation at
S262. To minimize baseline protein kinase C (PKC) activity, and
thus baseline levels of pS262-Cx43, cardiomyocytes were kept in
low serum (0.5% fetal bovine serum) for 48 h before stimula-
tion, as described previously (Doble et al., 2004). Myocytes were
then subjected or not to a brief 15-min pre-incubation with TGFβ
(5 ng/ml), and then stimulated with FGF-2 (10 ng/ml) for 30 min.
FGF-2 signiﬁcantly increased the anti-pS262-Cx43 signal, migrat-
ing at 45 kDa, in the absence of TGFβ pre-treatment, as expected
from previous studies (Doble et al., 2004); Figure 2. The stim-
ulatory effect of FGF-2 was, however, completely prevented in
cells pre-treated with TGFβ; Figure 2. The faster migrating pS262-
Cx43 observed in the previous experiment (Figure 1) was not
detectable in cultures kept in low serum and may be a character-
istic of cultures grown under conditions promoting proliferative
growth.
EFFECT OF INHIBITION OF TGFβ SIGNAL TRANSDUCTION ON GROWTH
SUPPRESSION BY OVEREXPRESSED Cx43
To examine the hypothesis that growth suppression by Cx43 is
mediated by downstream activation of TGFβ signal transduc-
tion, cardiomyocyte cultures were subjected to Cx43 or Cx43-CT
overexpression, in a background of pharmacological (SB431542)
TGFβRI inhibition. BrdU labeling index (proportion of cardiomy-
ocyte nuclei incorporating BrdU, over total number of cardiomy-
ocyte nuclei) was determined 2 days later, as a measure of relative
DNA synthesis ability.We have established in previous studies that
cardiomyocyte labeling index determinations aremirrored by, and
are therefore representative of, cell number determinations (Kar-
dami, 1990; Pasumarthi et al., 1996). The BrdU labeling index
of control groups, maintained in growth-stimulating conditions
(FGF-2-supplemented serum), varied between 0.25 and 0.30 in
different primary cardiomyocyte preparations.
Figure 3A compares normalized BrdU labeling index between
the various groups, where the value for the control group, sub-
jected to treatment with an empty adenoviral vector (Vector),
FIGURE 2 |TGFβ prevents the FGF-2-induced stimulation of Cx43
phosphorylation at S262. Representative western blots of cardiomyocyte
cultures stimulated with FGF-2 (10 ng/ml) in the absence or presence of
TGFβ pre-treatment for 15 min, as indicated. Corresponding normalized
densitometry-based data are also included. ** and ns correspond to
P < 0.01, or P > 0.05; n = 3.
was arbitrarily deﬁned as 1. In the absence of Cx43 or Cx43-
CT overexpression, inhibition of TGFβRI by SB431542 elicited
a signiﬁcant increase in BrdU incorporation (P < 0.05), as
anticipated from successful inhibition of baseline TGFβ signal
transduction (Sheikh et al., 2004). In the absence of SB431542,
overexpression of Cx43, or Cx43-CT elicited a robust inhibition of
cardiomyocyte BrdU labeling index, compared to Vector-treated
controls, in agreement with our previous report that inhibition
of cardiomyocyte DNA synthesis by Cx43 does not require the
channel-forming portion of the molecule (Kardami et al., 2007).
The presence of SB431542 was unable to reverse/prevent the
inhibitory effects of Cx43, or Cx43-CT overexpression, indicating
that suppression of DNA synthesis by Cx43, or Cx43-CT over-
expression does not depend on activation of TGFβRI. In fact it
would appear that Cx43, or Cx43-CT, overexpression, blocked
the ability of SB431542 to increase baseline cardiomyocyte DNA
synthesis. This suggested the possibility that Cx43 overexpression
may have somehow blunted the ability of SB431542 to inhibit
TGFβRI. If that were the case, SB431542 would not be able
to prevent the downstream phosphorylation and activation of
Smad2 (pSmad2). We therefore tested the status of Smad2 activa-
tion (pSmad2, phosphorylated at serines 465/467) in response to
SB431542, Cx43-, Cx43-CT, and a Cx43 phosphorylation mutant
(S262A-Cx43). Representative data are shown in Figure 3B.
SB431542 eliminated baseline Smad2/3 activation under control
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FIGURE 3 | (A) Pharmacological inhibition of TGFβRI does not affect
suppression of DNA synthesis by overexpressed Cx43 or Cx43-CT. The
y -axis shows normalized BrDU labeling index of cardiomyocytes
transduced either with an empty adenoviral vector, or adenoviral vectors
expressing Cx43, or channel-domain-deﬁcient Cx43-CT, and subjected
(or not) to SB431542 treatment (indicated by + or –, respectively).
Comparisons between groups are indicated by brackets (*P < 0.05,
two-way ANOVA, n = 24; data are mean + SEM). (B) Smad2 activity
(pSmad2), or its inhibition by SB431542, are not affected by overexpression
of Cx43, S262A-Cx43, or Cx43-CT.Western blots (representative of n = 2)
showing the effect of ±SB431542, on pSmad2, and total Smad2, in
myocytes transduced either with an empty adenoviral vector (Vector) or
with adenoviral vectors expressing Cx43, S262-Cx43, or Cx43-CT, as
indicated. Expression of the transduced genes was veriﬁed by western
blotting or immunoﬂuorescence (data not shown).
conditions, validating its ability to block downstream TGFβ-
TGFR1 signal transduction. The ability of SB431542 to prevent
baseline Smad2/3 activation was maintained in the presence of
Cx43, Cx43-CT, and S262A-Cx43 overexpression. Furthermore,
none of the overexpressed proteins (Cx43, Cx43-CT, S262A-Cx43)
appeared to affect baseline levels of pSmad2/3; no discernible
changes were observed in total Smad2/3 in any of the groups
tested.
The effect of directly inhibiting Smad2 (by expressing a cDNA
for Smad2-DN) on cardiomyocyte BrdU labeling index, in the
absence or presence of Cx43 or S262A-Cx43 overexpression, was
also examined. Expression of Smad2-DN signiﬁcantly increased
cardiomyocyte labeling index over control cells (Figure 4A). As
expected, expression of S262A-Cx43 decreased BrdU incorpora-
tion signiﬁcantly compared to controls; expression of wild type
Cx43 exerts a similar inhibitory effect (Figure 3A). The effect of
S262A-Cx43, as well as wild type Cx43 remained unchanged in
the presence of Smad2-DN (Figure 4A and unpublished obser-
vations). The inability of Smad2-DN to reverse the inhibitory
effect of S262A-Cx43 may be linked to the inability of the mutant
FIGURE 4 | (A) Inhibition of TGFβRII does not affect suppression of DNA
synthesis by Cx43 overexpression. The y -axis shows normalized BrdU
labeling index of cardiomyocytes transduced with an empty adenoviral
vector (Vector) or adenoviral vectors expressing Cx43, TGFβRII-DN, alone or
in combination, as indicated. (B) Inhibition of Smad2 does not affect
suppression of DNA synthesis by overexpressed S262A-Cx43. The y -axis
shows normalized BrdU labeling index of cardiomyocytes transduced with
an empty adenoviral vector (vector) or adenoviral vectors expressing
S262A-Cx43, or Smad2-DN, or a combination of both. Data are shown as
mean + SEM; brackets indicate comparisons between groups. **, *, and
ns correspond to P < 0.01, P < 0.05, P > 0.05. Expression of the
transduced genes was veriﬁed by western blotting (data not shown).
Cx43 to become phosphorylated at amino-acid 262, providing an
irreversible signal.
Inhibition of TGFβRII by overexpressing TGFβRII-DN signif-
icantly increased BrdU labeling index in cardiomyocytes, as we
reported previously (Sheikh et al., 2004). This effect was prevented
in the presence of Cx43 overexpression (Figure 4B).
Taken together, our ﬁndings with inhibitors of early TGFβ
signal transduction are consistent with a scenario where Cx43-
mediated growth suppression occurs downstream of TGFβ/
TGFβRII/TGFβRI/pSmad2 signaling.
Finally we asked if inhibition of cardiomyocyte DNA synthesis
by Cx43 was additive to that by TGFβ. As shown in Figure 5,
addition of TGFβ or overexpression of Cx43, both exerted a
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FIGURE 5 | Suppression of DNA synthesis by Cx43 overexpression is
not additive to that byTGFβ.The y -axis shows normalized BrdU labeling
index of untreated cardiomyocytes (Control); cardiomyocytes treated with
TGFβ; subjected to Cx43 overexpression; or treated with TGFβ in the
presence of Cx43 overexpression, as indicated. Absolute BrdU labeling
index was at 0.3. Data are shown as mean ± SEM. Brackets show
comparisons between groups. ** and ns correspond to P < 0.01, or
P > 0.05.
signiﬁcant inhibitory effect on BrdU labeling index, assessed 1 day
after treatment. The degree of inhibition by TGFβ was not signif-
icantly different to that by Cx43. The extent of inhibition of BrdU
incorporation by combined use of TGFβ and Cx43 overexpression
was not signiﬁcantly different to that of either inhibitor alone. The
absence of an additive effect on DNA synthesis inhibition suggests
that TGFβ-triggered signals, and Cx43-mediated signals, are com-
ponents of the same pathway, where, as indicated by our results
shown in the previous Figures (1–5), Cx43-triggered signals are
downstream of early TGFβ signal transduction.
Experimental evidence presented here in combination with
previous work pointed to a hypothetical scenario where phos-
phorylation of Cx43 at S262 allows this protein to act as a switch
between pro-mitotic and anti-mitotic signaling, as illustrated in
Figure 6.
DISCUSSION
Connexin-43 is constitutively phosphorylated at multiple sites,
ensuring correct trafﬁcking of this protein to the plasma mem-
brane as well as assembly of connexons and channel functionality
(Solan and Lampe, 2009). In addition to the constitutively phos-
phorylated sites, speciﬁc sites at the C-terminal tail of Cx43
can become phosphorylated in response to growth factor- or
oncogene-linked signaling, preventing Cx43 from suppressing
cell proliferation. For example, the src-targeted tyrosines 247
and 265 can affect the ability of Cx43 to inhibit proliferation of
glioma cells (Herrero-Gonzalez et al., 2010); serines 255, 262, 279,
282 are reported as targets of mitogen-activated protein kinase
pathways, and, their phosphorylation allows for platelet-derived
growth factor-triggered mitotic stimulation of vascular smooth
FIGURE 6 | A hypothetical model for the regulation of cardiomyocyte
proliferation by Cx43 phosphorylation at S262. Mitogen
(FGF-2)-triggered signaling includes activation of cognate receptor (FGFR,
ﬁbroblast growth factor receptors), downstream activation of PKCε,
followed by increased interaction between PKCε and Cx43, and
phosphorylation of Cx43 at S262. This phosphorylation event blocks the
ability of Cx43 to act as a suppressor of DNA synthesis, and allows FGF-2
signaling to promote cell cycle progression. Early TGFβ-triggered signaling
includingTGFβRII/RI and Smad2/3 activation results in decreased levels of
pS262-Cx43, allowing Cx43 to act as a growth suppressor. TGFβ signaling
may: activate phosphatases such as PP1, or PP2A, to affect Cx43
dephosphorylation; prevent the FGF-2-induced PKCε activation, and/or
prevent PKCε/Cx43 interaction and thus Cx43 phosphorylation. These
possibilities are indicated by question marks. Cx43-, as well as
TGFβ-mediated inhibition of cell proliferation is achieved via downstream
activation of cell cycle inhibitors p21/p27.
muscle cells (Johnstone et al., 2012). In cardiomyocytes, the
FGF-2-induced mitotic stimulation is accompanied by increased
phosphorylation of Cx43 at S262, mediated by PKCε (Doble et al.,
2000, 2004). To understand the role of phosphorylation at S262
on the ability of Cx43 to suppress growth, in previous studies we
used Cx43 phosphorylation mutants to simulate either constitu-
tive phosphorylation (S262-to-aspartate (D) substitution) or lack
of phosphorylation (S262A) at the S262 site. The ability of Cx43 to
suppress DNA synthesis was found to be maximal in cells express-
ing S262A-Cx43 but absent in cells expressing S262D-Cx43 (Doble
et al., 2004; Dang et al., 2006). Overall our previous work indicated
that pS262-Cx43 is “permissive” for DNA synthesis, allowing cells
to progress through the cell cycle in response to growth factor
stimulation. One may therefore consider the notion that condi-
tions and factors known to inhibit cell proliferation may actively
prevent the phosphorylation of Cx43 at speciﬁc sites. TGFβ is
one such factor, known for its cytostatic properties in many sit-
uations (Massague, 2000). Because TGFβ signaling counteracts
the stimulatory effect of FGF-2 on cardiomyocytes DNA synthesis
(Kardami, 1990), we hypothesized that TGFβ may promote the
“growth inhibitory” state of Cx43, by preventing its phosphoryla-
tion at S262. This question was addressed in both an acute as well
as a more “chronic” setting, in culture.
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In the acute setting, a brief pre-treatment with TGFβ rendered
cardiomyocytes incapable of responding to FGF-2 as shown by
their blunted ability to upregulate pS262-Cx43; the acute response
has “chronic” consequences as it is accompanied by a blunted
DNA synthesis and cell proliferation response (Kardami, 1990);
see also Figure 5. In a more “chronic” scenario, we tested the con-
sequences of inhibiting constitutive TGFβ signal transduction on
endogenous pS262-Cx43 levels. The biological effects of TGFβ are
transduced by binding to plasma membrane receptors, TGFβRII
and TGFβRI, downstream activation/phosphorylation of the reg-
ulatory Smads (Smad2 and Smad3), their interaction with Smad4,
nuclear translocation and activation of speciﬁc gene expression
(Massague and Wotton, 2000; Heldin et al., 2009). Inhibition at
the level of TGFβR1 was achieved through the use of SB431542,
which inhibits TGFRI (ALK5) by acting as a competitive ATP
binding site kinase inhibitor (Inman et al., 2002). In cardiomy-
ocytes, which express ALK5, SB431542 is effective in preventing
downstream activation (phosphorylation) of Smad2 as shown by
(Waghabi et al., 2002), and conﬁrmed here. To speciﬁcally tar-
get the activity of TGFβRII, which acts as a co-receptor with
TGFβRI, we overexpressed a kinase-deﬁcient TGFβRII which has
been shown to be effective in inhibiting endogenous TGFβRII in a
DN fashion (Sheikh et al., 2004). Finally, Smad2 activation (phos-
phorylation) was prevented by overexpressing Smad2-DN. All of
these inhibitors increased endogenous levels of pS262-Cx43, with-
out affecting total Cx43 protein levels, indicating that early TGFβ
signal transduction (engaging the activity of TGFβRII andTGFβRI
and resulting in Smad2 phosphorylation) downregulates pS262-
Cx43. This may occur by: directly preventing the FGF-2-induced
activation of PKCε which acts as an upstream phosphorylating
kinase for Cx43; by preventing Cx43 interaction and/or phospho-
rylation by the PKCε; by activating phosphatase(s) that would
cause Cx43 dephosphorylation. There is evidence to support the
latter possibility: TGFβ signaling activates protein phosphatase
(PP)-2A (Petritsch et al., 2000), which has been reported to tar-
get Cx43 for dephosphorylation (Ai et al., 2011). Other potential
phosphatases implicated in Cx43 dephosphorylation include PP1
and PP2B (Jeyaraman et al., 2003). There is at present limited
information as to potential effects of TGFβ on PKCε activity or
expression, or on the PKCε/Cx43 interaction. It is of interest, how-
ever, that PKCε is promoting the proliferation of cells, including
cardiomyocytes (Kardami et al., 2003), and has an antithetical rela-
tionship with TGFβ regarding the control of CD4+ T-lymphocyte
proliferation (Mirandola et al., 2011).
In parallel to increasing endogenous pS262-Cx43, inhibition
of constitutive TGFβ signal transduction increased cardiomyocyte
DNA synthesis, providing further validation to the notion that
Cx43 phosphorylation at S262 is permissive for mitogenic stimu-
lation. It should, however, be noted that inhibition of constitutive
TGFβ signal transduction was unable to reverse the inhibitory
effects of overexpressed Cx43. It is possible that overexpressed
Cx43 (or Cx43-CT) overwhelm the endogenous cellular machin-
ery (kinases/phosphatases) affected by inhibition of baseline TGFβ
signaling. In broad agreement with this notion, we have previ-
ously observed that only a small fraction of overexpressed Cx43,
or Cx43-CT, become phosphorylated at S262 under normal cul-
ture conditions, requiring stimulation with a highly potent PKC
activator, phorbol-12-myristate-13-acetate, for Cx43 to become
mostly phosphorylated at that site (Dang et al., 2006). A likely
explanation therefore for the apparent discrepancy of our ﬁnd-
ings with endogenous versus overexpressed Cx43 is that any
signals (kinases/phosphatases) activated or dis-inhibited by block-
ing baseline TGFβ signaling may be inadequate to promote or
sustain substantial phosphorylation at S262 when Cx43 is present
at above-normal levels.
Previous studies using a cardiac cell line, atria-derived HL-1,
indicated that Cx43, of unknown phosphorylation status, acti-
vated TGFβ transcriptional activity, by activating TGFβRI, and
promoting Smad2/3 phosphorylation andnuclear translocation; it
was suggested that Cx43-dependent suppression of cardiomyocyte
proliferative growth reﬂected downstream activation of Smad2/3
(Dai et al., 2007). This would position Cx43 expression upstream
of TGFβRI-pSmad2 signal transduction, in apparent contrast to
ﬁndings presented here. We showed that ectopic expression of
Cx43 inhibited DNA synthesis regardless of the status of TGFβRI
or Smad2/3 activation; in addition neither Cx43 nor Cx43-CT
overexpression had any discernible effect on relative pSmad2 levels
in our system. Our data therefore suggested that Cx43-mediated
inhibition of DNA synthesis is not mediated by downstream
activation of TGFβ signals. It is possible that these differences
may reﬂect differences between experimental approaches (gain-
of-function in the case of overexpression versus loss-of-function
in knock-down studies) and/or cell types, namely the mouse atrial
HL-1 cell line versus rat primary ventricular cardiomyocytes used
here. Also, as Dai et al. (2007) used TGFβ transcriptional activa-
tion as their end-point, there was no information as to how the
observed Smad2/3 and/or Cx43 expression changes affected DNA
synthesis in their system.
The precise molecular mechanism by which Cx43 and pS262-
Cx43 affect proliferative growth remains to be determined. The
role of subcellular localization of Cx43 is not clear: Cx43-CT,
which, unlike Cx43, localizes to the cytosol and nucleus, retains
inhibitory activity (Dang et al., 2003; Kardami et al., 2007), sug-
gesting that localization at cell–cell contact sites and/or gap junc-
tion function are not crucial determinants of growth inhibitory
activity. Furthermore, phosphorylation at S262 (simulated by
expression of S262D-Cx43, or -Cx43-CT) blocked the inhibitory
properties of not only Cx43 but also Cx43-CT, without affect-
ing their respective distinct localizations, at plasma membrane
versus cytosolic/nuclear sites, inHEK293 cells; unpublished obser-
vations and as shown previously (Dang et al., 2003, 2006). It is
of interest, however, that Cx43 (Boengler et al., 2005) as well as
a C-terminal containing fragment of Cx43 (Kardami et al., 2007)
have also been detected in cardiac mitochondria. Mitochondria
play an important role in cell cycle regulation (Antico Arciuch
et al., 2012), and therefore future studies should examine whether
mitochondrial Cx43, and its potential phosphorylation at S262,
modulate mitochondrial function in this context.
In conclusion, our studies suggest the following model to
describe the relationship between TGFβ and Cx43-mediated
growth suppression in cardiomyocytes; Figure 6. TGFβ-triggered
early signal transduction, involving activation of TGFβRII/RI and
phosphorylation of Smad2, reduces relative levels of pS262-Cx43,
by either preventing the growth factor-induced PKCε activation,
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or PKCε/Cx43 interaction, and/or by activating Cx43-targeting
phosphatase(s). Cx43 lacking phosphorylation at S262 possesses
growth inhibitory activity, blocks growth factor (FGF-2) sig-
nals from stimulating cell cycle progression, and mediates or at
least contributes to inhibition of DNA synthesis by TGFβ. It has
been established that both TGFβ-, and Cx43-, mediated sup-
pression of cell proliferation are achieved by upregulating the
cyclin-dependent kinase inhibitors p21/p27 which control cell
cycle arrest (Sanchez-Alvarez et al., 2006; Abbas and Dutta, 2009;
Bauer et al., 2012), and thus these signals are proposed to be
activated downstream of Cx43 lacking phosphorylation at S262.
Mitogens, such as FGF-2, overcome/attenuate inhibition of DNA
synthesis byCx43bypromoting activationof PKCεwhich interacts
with, and phosphorylates Cx43 at S262. The ability of FGF-2 to
overcome the growth inhibitory effect of Cx43 on cardiomyocytes
is likely to depend on expression of appropriate levels of signal-
transducing machinery [FGF-2 receptors, active PKCε, inactive
phosphatase(s)] to achieve and/or sustain phosphorylation of
endogenous Cx43 at S262.
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